GO
Loading...

Covidien PLC

More

  • Why S&P 1,500 May Signal Stock Rally Has Peaked Friday, 25 Jan 2013 | 12:26 PM ET

    The S&P 500 regained the 1,500 level for the first time in more than five years, but that's a milestone that could also trigger a pause, analysts say.

  • Bulls Gear Up for Another Run at 1,500 on S&P Thursday, 24 Jan 2013 | 9:35 PM ET

    Wall Street's bull could take another run at the psychologically important 1,500 level as early as Friday, but that's a level that could also trigger a pause, analysts say.

  • Will Tech Earnings Charge Up the Stock Market Rally? Friday, 18 Jan 2013 | 8:33 PM ET
    Google Maps app for Apple ios.

    A flood of earnings reports, including major technology and industrial companies, could make or break the stock market’s surprise January rally in the week ahead.

  • Ryan: Is the Health Care Sector 'Healthy?' Monday, 7 Jan 2013 | 2:13 PM ET

    CNBC Contributor Barbara Ryan is taking the pulse of health care stocks at this year's "Woodstock" of health care.

  • Stocks to Watch: P, FB, MFRM & More Wednesday, 5 Dec 2012 | 8:07 AM ET

    Here are Wednesday's morning movers.

  • Analyst downgrades Johnson & Johnson to "sell" Tuesday, 9 Oct 2012 | 12:00 AM ET

    NEW YORK-- Goldman Sachs downgraded Johnson& Johnson, saying Tuesday that the current share price has captured all the potential for improved growth. However, Goldman analyst Jami Rubin wrote that Johnson& Johnson comes up short in the two areas she sees as likely to boost stock prices, new prescription drugs and capital allocation.

  • *Announces FDA 510 clearance and ce mark for Nellcor (TM) bedside. *Says new system will be available in the United States and throughout the eea. in the next few months.

  • Covidien completes $100M CNS Therapeutics deal Tuesday, 2 Oct 2012 | 4:35 PM ET

    NEW YORK-- Drug and medical device maker Covidien PLC said Tuesday it completed its $100 million purchase of CNS Therapeutics. Covidien announced it was buying CNS on Sept. 24. CNS is now part of Covidien's Mallinckrodt pharmaceuticals business.

  • Covidien CEO on Earnings & Obamacare     Thursday, 26 Jul 2012 | 6:25 PM ET

    Joe Almeida, Covidien plc chairman, president & CEO, discusses his company's medical device products and recent earnings, and the Supreme Court's health-care ruling.

  • Corporate Splits, Just as Easy as TomKat Divorce Thursday, 12 Jul 2012 | 2:21 PM ET

    Jim Cramer’s researcher, Nicole Urken, takes a look at some pockets of value creation in this unpredictable market.

  • Covidien CEO Talks Acquisitions Monday, 9 Jul 2012 | 8:41 PM ET

    Joe Almeida, Covidien president & CEO, discussed his company's strategies for growth and much more.

  • Johnson & Johnson Remains Too Big to Succeed Thursday, 10 May 2012 | 12:28 PM ET
    Johnson & Johnson

    Few stock sectors are as reliable as drugs and health care, and astute investors know that companies such as Merck, Pfizer, and Abbott Laboratories have delivered healthy returns over the years. One stock that investors have become less enamored with, however, is Johnson & Johnson.

  • Your First Move For Tuesday February 28th Monday, 27 Feb 2012 | 7:06 PM ET

    Here's our Fast Money Final Trade. Our gang gives you tomorrow's best trades, right now!

  • 5 Deal-Ready Stocks Loved by Hedge Funds Thursday, 16 Feb 2012 | 3:52 PM ET

    Every quarter hedge funds and large investors file their holdings with the SEC, revealing value picks, cyclical bets, growth opportunities and activist pushes. TheStreet.com details five stocks that hedge funds flocked to.

  • Activist Hedge Fund Moves Into Netflix, Gold Wednesday, 15 Feb 2012 | 1:05 PM ET

    Barry Rosenstein, founder of Jana Partners, is best known as an activist investor. The hedge fund manager made intriguing moves in the fourth quarter, buying more shares of Apple and making an outsized bet on Marathon Petroleum.

  • Cramer makes the call on viewers' favorite stocks.

  • What's Shaking: Friday's Early Movers Friday, 20 Jan 2012 | 8:31 AM ET

    Happy Friday! Take a look at some of this morning's early movers:

  • Cramer: Why Covidien is Now a Buy Monday, 19 Dec 2011 | 7:04 PM ET

    The “Mad Money” host explains the catalyst behind his call.

  • Cramer: Cash in on Covidien Break Up.     Monday, 19 Dec 2011 | 6:45 PM ET

    Breaking up can be a fantastic way to send a stock higher, says Mad Money's Jim Cramer, and now that Covidien is spinning off its pharma business, it unlocks a lot of value for shareholders, and is a screaming "buy".

  • Your First Move for Friday December 16th Thursday, 15 Dec 2011 | 7:46 PM ET

    Here's our Fast Money Final Trade. Our gang gives you tomorrow's best trades, right now!